1. Indications:

Ruxonib (Ruxolitinib) 1.5% is indicated for the treatment of:

• Moderate to severe atopic dermatitis (eczema) in adults and adolescents aged 12 years and older who are candidates for systemic therapy.

2. Pharmacology:

Ruxonib (Ruxolitinib) 1.5% exerts its pharmacological effects by selectively inhibiting the activity of Janus kinase (JAK) enzymes, particularly JAK1 and JAK2. By inhibiting JAK enzymes, Ruxonib interferes with signaling pathways involved in inflammation and immune response, thereby reducing the symptoms associated with atopic dermatitis, such as redness, itching, and skin lesions.

3. Dosage and Administration:

The recommended dosage of Ruxonib (Ruxolitinib) 1.5% may vary depending on the severity of the skin condition and individual patient characteristics. Typically, a thin layer of Ruxonib cream should be applied topically to the affected areas of the skin twice daily. Treatment should continue until improvement of symptoms is observed, and then the frequency of application may be adjusted as directed by the healthcare provider.

4. Interaction:

Ruxonib (Ruxolitinib) 1.5% applied topically is less likely to interact with other medications compared to systemic formulations. However, patients should still inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.

5. Side Effects:

Common side effects associated with Ruxonib (Ruxolitinib) 1.5% topical cream may include:

• Mild skin irritation (e.g., redness, itching, burning) at the application site
• Dry skin
• Erythema (skin redness)
• Rash

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Ruxonib (Ruxolitinib) 1.5% topical cream, patients should be aware of the following precautions:

• Ruxonib cream is for external use only. Avoid contact with eyes, mucous membranes, and open wounds.
• Discontinue use of Ruxonib cream if irritation or sensitization occurs and consult a healthcare provider.
• Ruxonib cream has not been studied in pregnant or breastfeeding women. Use during pregnancy or breastfeeding should be avoided unless the potential benefit justifies the potential risk to the fetus or infant.

7. Overdose Effects:

There is limited information available regarding the potential effects of overdose with topical Ruxonib (Ruxolitinib) 1.5% cream. In case of accidental ingestion or excessive topical application leading to adverse reactions, supportive care should be initiated, and symptomatic treatment may be administered as necessary. Patients should seek medical attention if significant systemic absorption or adverse effects are suspected.